Creatine Monohydrate

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.

Notes

Date

February 24, 2023

Proper name(s), Common name(s), Source information

Table 1. Proper name(s), Common name(s), Source information
Proper name(s) Common name(s) Source information
Source material(s) Preparation(s)
N-(Aminoiminomethyl)-N-methylglycine monohydrate Creatine monohydrate Creatine monohydrate Synthetic

References: Proper name: O' Neil et al. 2013, US NLM 2011; Common name: O' Neil et al. 2013, US NLM 2011; Source information: O' Neil et al. 2013, Weiss and Krommer 1998.

Route of administration

Oral

Dosage form(s)

This monograph excludes foods or food-like dosage forms as indicated in the Compendium of Monographs Guidance Document.

Acceptable dosage forms for oral use are indicated in the dosage form drop-down list of the web-based Product Licence Application form for Compendial applications.

Note
Liquids and solutions are not permitted due to lack of stability of the finished product (Dash and Sawhney 2002).

Use(s) or Purpose(s)

Dose(s) and Duration(s) of use

Subpopulation(s)

Adults 18 years and older

Quantity(ies)

Table 2. Dose(s) and duration(s) of use for creatine monohydrate
Phase(s) Dose(s) (g/day) Duration(s) of use
Loading Phase Option 11 15-20; not to exceed 5 g per dose 5-7 days
Option 22 3-5 Use for a minimum of 4 weeks
Maintenance Phase3 2-5 No statement required

1 References: Okudan and Gokbel 2005; Preen et al. 2003; Bemben et al. 2001; Vandenberghe et al. 1997; Hultman et al. 1996
2 Reference: Hultman et al. 1996
3 References: Preen et al. 2003; Bemben et al. 2001; Volek et al. 1999; Vandenberghe et al. 1997; Hultman et al. 1996

Direction(s) for use

Table 3. Direction(s) for use
Phase(s) Direction(s) for use
Loading Phase Option 1 Step 1 (Loading Phase): Start with a loading phase of 5-7 days (15-20 g/d) and follow with a maintenance phase (2-5g/d)
Option 2 Step 1 (Loading Phase): Start with a loading phase of 4 weeks (3-5 g/d) and follow with a maintenance phase (2-5 g/d)
Maintenance Phase Step 2 (Maintenance Phase): No statement required

Risk information

Caution(s) and warning(s)

Contraindication(s):

No statement required.

Known adverse reaction(s):

No statement required.

Non-medicinal ingredients

Must be chosen from the current Natural Health Products Ingredients Database (NHPID) and must meet the limitations outlined in the database.

Storage conditions

Must be established in accordance with the requirements described in the Natural Health Products Regulations (NHPR)

Specifications

References cited

References reviewed